Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243272 | 0.84 | TRPA1 (0.47) | SLC7A5CTSSCTSKTRPA1TRPV4 | |
| SCHEMBL5115641 | 0.83 | SCN9A (0.36) | DPP4 | |
| SCHEMBL5109170 | 0.81 | SLC7A5 (0.43) | SLC7A5DPP4MAPK14LTA4HAPP | |
| SCHEMBL5109997 | 0.81 | SLC7A5 (0.40) | SLC7A5DPP4MAPK14LTA4HAPP | |
| SCHEMBL29529375 | 0.80 | CTSS (0.52) | CTSSCTSKTRPA1 | |
| SCHEMBL21029611 | 0.77 | SLC7A5 (0.45) | SLC7A5DPP4MAPK14LTA4HAPP | |
| SCHEMBL25317908 | 0.77 | DPP4 (0.45) | SLC7A5CTSSCTSKDPP4LTA4H | |
| SCHEMBL18256468 | 0.76 | SLC7A5 (0.44) | SLC7A5DPP4MAPK14LTA4HAPP | |
| SCHEMBL19088473 | 0.76 | SLC7A5 (0.44) | SLC7A5DPP4MAPK14LTA4HAPP | |
| SCHEMBL29551946 | 0.76 | SLC7A5 (0.44) | SLC7A5DPP4MAPK14LTA4HAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1651629-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050038104-A1 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012283-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038104-A1 | Substitute benzothiophene compounds | TST, SULT1E1, LTC4S | SLC7A5 2920/4885AOC3 714/4885CTSS 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.